Phase III Hallmark DUAL: ASV+DCV (Nulls/Partials, Intolerants/Ineligibles. Naives) (Hallmark DUAL)
A Phase 3 Study With Asunaprevir and Daclatasvir (DUAL) for Null or Partial Responders to Peginterferon Alfa and Ribavirin (P/R), Intolerant or Ineligible to P/R Subjects and Treatment-Naive Subjects With Chronic Hepatitis C Genotype 1b Infection
Sponsor: Bristol-Myers Squibb
Listed as NCT01581203, this PHASE3 trial focuses on Hepatitis C Virus and remains completed. Sponsored by Bristol-Myers Squibb, it has been updated 9 times since 2012, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
9 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE3
▶ Show 4 earlier versions
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
May 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Adelaide, Australia , Alicante, Spain , Amsterdam, Netherlands , Auckland, New Zealand , Aurora, United States , Barcelona, Spain , Bedford Park, Sa, Australia , Berlin, Germany , Bialystok, Poland , Bonn, Germany and 87 more locations